Search research articles
Contact Us
Filters
Showing results (181-190 of 268) with videos related to
Page
of 27
Sort By:
Disease Models & Mechanisms
|
December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation
Takuo Hayashi, Igor Odintsov, Roger S Smith, et al.
JCO Precision Oncology
|
June 14, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Michael Offin, Robin Guo, Stephanie L Wu, et al.
JCO Precision Oncology
|
March 30, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced <i>ALK</i>-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers
Emily A Miao, Beow Yeap, Sameh Daher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2020
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, et al.
JCO Precision Oncology
|
April 7, 2018
Successful Targeted Therapy of Refractory Pediatric <i>ETV6-NTRK3</i> Fusion-Positive Secretory Breast Carcinoma
Neerav Shukla, Stephen S Roberts, Mollah O Baki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
Cancer Research Communications
|
February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC
Mari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
W Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions
Hiroki Sato, Adam J Schoenfeld, Evan Siau, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 268) with videos related to
Sort By:
Page
of 27
Disease Models & Mechanisms
|
December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation
Takuo Hayashi, Igor Odintsov, Roger S Smith, et al.
JCO Precision Oncology
|
June 14, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Michael Offin, Robin Guo, Stephanie L Wu, et al.
JCO Precision Oncology
|
March 30, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced <i>ALK</i>-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers
Emily A Miao, Beow Yeap, Sameh Daher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2020
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, et al.
JCO Precision Oncology
|
April 7, 2018
Successful Targeted Therapy of Refractory Pediatric <i>ETV6-NTRK3</i> Fusion-Positive Secretory Breast Carcinoma
Neerav Shukla, Stephen S Roberts, Mollah O Baki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
Cancer Research Communications
|
February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC
Mari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
W Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions
Hiroki Sato, Adam J Schoenfeld, Evan Siau, et al.
Page
of 27